On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of ...
Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...
The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its requests for ...
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...
The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, ...
The Massachusetts Democrat is working with a Missouri Republican, and House members from each party, to press the FTC to ...
The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...
The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's Express Scripts—marked up prices at their pharmacies by hundreds or thousands ...